Risperdal Settlement

Johnson & Johnson will settle a misdemeanor criminal charge involving the marketing of its psychiatric drug Risperdal.

J&J said in a regulatory filing that the agreement related to an allegation that the company promoted Risperdal for unapproved uses. The agreement, which has not been finalized, was disclosed in a filing with the Securities and Exchange Commission.

The settlement amount was not disclosed.